Bexlosteride is primarily used in the treatment of benign prostatic hyperplasia (BPH), a condition characterized by the enlargement of the prostate gland. It works by inhibiting the enzyme 5-alpha reductase, which is responsible for converting testosterone into dihydrotestosterone (DHT). By reducing DHT levels, Bexlosteride helps to shrink the prostate, alleviating symptoms such as difficulty in urination, frequent urination, and incomplete bladder emptying. This makes it a valuable option for improving urinary function and quality of life in men suffering from BPH. Additionally, it may be investigated for its potential role in treating androgen-related conditions, such as male pattern baldness, due to its mechanism of action.